Țară: Canada
Limbă: engleză
Sursă: Health Canada
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE)
LABORATOIRE RIVA INC.
J01FA10
AZITHROMYCIN
250MG
TABLET
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) 250MG
ORAL
6/100
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0126072001; AHFS:
APPROVED
2006-03-15
manufacturer’s standard PRODUCT MONOGRAPH PR RTVA - AZITHROMYCIN Azithromycin Dihydrate Tablets 250 mg Azithromycin ( supplied as azithromycin dihydrate ) , Antibacterial Agent LABORATOIRE RIVA INC . 660 Boul . Industriel , Blainville , Quebec J 7 C 3 V 4 DATE OF REVISION : August 21 , 2020 www . labriva . com CONTROL NO . : 242159 _RIVA_ _-_ _AZITHROMYCIN_ _-_ _Product_ _Monograph_ _Page_ _l_ _of_ _63_ TABLE OF CONTENTS PART I : HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION INDICATIONS AND CLINICAL USE CONTRAINDICATIONS WARNINGS AND PRECAUTIONS ADVERSE REACTIONS DRUG INTERACTIONS DOSAGE AND ADMINISTRATION OVERDOSAGE ACTION AND CLINICAL PHARMACOLOGY STORAGE AND STABILITY DOSAGE FORMS , COMPOSITION AND PACKAGING 3 3 3 4 5 9 15 20 21 21 24 24 PART II : SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION CLINICAL TRIALS DETAILED PHARMACOLOGY MICROBIOLOGY TOXICOLOGY REFERENCES 25 25 26 31 36 39 54 PATIENT MEDICATION INFORMATION 59 _RIVA_ _-_ _AZITHROMYCIN_ _-_ _Product_ _Monograph_ _Page_ _2_ _of_ _63_ anufacturer’s standard (group A β PR RIVA - AZITHROMYCIN Azithromycin Dihydrate Tablets M PART I : HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION DOSAGE FORM / STRENGTH NONMEDICAL INGREDIENTS ROUTE OF ADMINISTRATION Dibasic calcium phosphate , croscarmellose sodium , pregelatinized starch , magnesium stearate , microcrystalline cellulose , purified water , sodium lauryl sulphate and lactose monohydrate . Oral Tablet / 250 mg Coating material : Hypromellose , lactose monohydrate , titanium dioxide , triacetin and D & C Red # 30 Aluminum lake . INDICATIONS AND CLINICAL USE RIVA - AZITHROMYCIN ( azithromycin dihydrate ) for oral administration is indicated for treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions . As recommended dosages , durations of therapy and applicable patient populations vary among these infections , see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Bec Citiți documentul complet